journal
MENU ▼
Read by QxMD icon Read
search

Gynecologic Oncology

journal
https://www.readbyqxmd.com/read/28427775/nonoperative-management-of-atypical-endometrial-hyperplasia-and-grade-1-endometrial-cancer-with-the-levonorgestrel-intrauterine-device-in-medically-ill-post-menopausal-women
#1
William D Baker, Stuart R Pierce, Anne M Mills, Paola A Gehrig, Linda R Duska
OBJECTIVE: To assess the endometrial response rates to treatment with the levonorgestrel intrauterine device in post-menopausal women with atypical hyperplasia/endometrial intraepithelial neoplasia and grade 1 endometrioid (AH/EC) endometrial carcinoma who are not surgical candidates. METHODS: Chart review was undertaken of patients with AH/EC who underwent levonorgestrel intrauterine device insertion by a gynecologic oncologist within two academic health systems between 2002 and 2013...
April 18, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28427776/autoantibody-biomarkers-for-the-detection-of-serous-ovarian-cancer
#2
Benjamin A Katchman, Diego Chowell, Garrick Wallstrom, Allison F Vitonis, Joshua LaBaer, Daniel W Cramer, Karen S Anderson
Objective The purpose of this study was to identify a panel of novel serum tumor antigen-associated autoantibody (TAAb) biomarkers for the diagnosis of high-grade serous ovarian cancer. METHODS: To detect TAAb we probed high-density programmable protein microarrays (NAPPA) containing 10,247 antigens with sera from patients with serous ovarian cancer (n=30 cases/30 healthy controls) and measured bound IgG. We identified 735 promising tumor antigens and evaluated these with an independent set of serous ovarian cancer sera (n=30 cases/30 benign disease controls/30 healthy controls)...
April 17, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28411948/reporting-denominator-data-is-essential-for-benchmarking-and-quality-standards-in-ovarian-cancer
#3
Andrew Phillips, Janos Balega, James Nevin, Kavita Singh, Ahmed Elattar, Sean Kehoe, Sudha Sundar
OBJECTIVE: Combined surgery and platinum-based chemotherapy is the internationally agreed standard therapy for advanced ovarian cancer (AOC). However international cancer registry datasets demonstrate a significant proportion of patients do not receive both or either therapies. Our objective was to evaluate the effect of total patient cohort data ('Denominator') on median overall survival (OS) and determine how frequently this was reported in literature. METHODS: We retrospectively reviewed OS outcomes for 593 patients diagnosed with AOC for 77 months at a regional cancer centre...
April 12, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28410756/perioperative-sexual-interest-in-women-with-suspected-gynecologic-malignancies
#4
C Emi Bretschneider, Jeannette T Bensen, Elizabeth J Geller, Paola A Gehrig, Jennifer M Wu, Kemi M Doll
OBJECTIVES: For women with gynecologic cancer, the impact of surgery on sexual interest and desire in the immediate and later postoperative period is not well characterized. The objective of this study was to report the perioperative trends of changing sexual interest and desire in a cohort of women undergoing surgery for suspected gynecologic malignancies. METHODS: This is an ancillary analysis of a cohort study analyzing health-related outcomes in women who underwent primary surgical management of a suspected gynecologic malignancy between 10/2013 and 10/2014...
April 12, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28410757/outpatient-desensitization-in-selected-patients-with-platinum-hypersensitivity-reactions
#5
REVIEW
David M O'Malley, Monica Hagan Vetter, David E Cohn, Ambar Khan, John L Hays
Platinum-based chemotherapies are a standard treatment for both initial and recurrent gynecologic cancers. Given this widespread use, it is important to be aware of the features of platinum hypersensitivity reactions and the subsequent treatment of these reactions. There is also increasing interest in the development of desensitization protocols to allow patients with a history of platinum hypersensitivity to receive further platinum based therapy. In this review, we describe the management of platinum hypersensitivity reactions and the desensitization protocols utilized at our institution...
April 11, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28410755/the-clinical-trials-crisis-in-gynecologic-oncology
#6
EDITORIAL
Marcela G Del Carmen, Christina M Annunziata, Laurel W Rice
No abstract text is available yet for this article.
April 11, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28400146/comparison-of-four-brief-depression-screening-instruments-in-ovarian-cancer-patients-diagnostic-accuracy-using-traditional-versus-alternative-cutpoints
#7
Eileen H Shinn, Alan Valentine, George Baum, Cindy Carmack, Kelly Kilgore, Diane Bodurka, Karen Basen-Engquist
OBJECTIVES: We compared the diagnostic accuracy of 4 depression screening scales, using traditional and alternative scoring methods, to the gold standard Structured Clinical Interview-DSM IV major depressive episode (MDE) in ovarian cancer patients on active treatment. METHODS: At the beginning of a new chemotherapy regimen, ovarian cancer patients completed the following surveys on the same day: the Center for Epidemiological Studies Depression Scale (CES-D), the Beck Depression Inventory Fast-Screen for Primary Care (BDI-FastScreen), the Patient Health Questionnaire-9 (PHQ-9), and a 1-item screener ("Are you depressed?")...
April 8, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28395896/objective-response-rate-is-a-possible-surrogate-endpoint-for-survival-in-patients-with-advanced-recurrent-ovarian-cancer
#8
Mohammed Kashif Siddiqui, Jerzy Tyczynski, Ankit Pahwa, Ancilla W Fernandes
OBJECTIVE: Evaluate literature to assess response rate as a surrogate endpoint of survival in ovarian cancer (OC). METHODS: Systematic review consistent with PRISMA criteria, identified randomized, controlled trials reporting overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) in recurrent OC. MEDLINE® and Embase® searches (year 2000-March 23, 2015) were augmented by bibliographic screening. Proposed surrogate measures (independent variables) were ORR and disease control rate...
April 7, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28392129/poly-adp-ribose-polymerase-parp-inhibitors-as-treatment-versus-maintenance-in-ovarian-carcinoma
#9
EDITORIAL
Whitney S Graybill, Bhavana Pothuri, Dana M Chase, Bradley J Monk
No abstract text is available yet for this article.
April 6, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28392128/is-parametrectomy-always-necessary-in-early-stage-cervical-cancer
#10
Glauco Baiocchi, Louise de Brot, Carlos Chaves Faloppa, Henrique Mantoan, Matheus Rodrigues Duque, Levon Badiglian-Filho, Alexandre Andre Balieiro Anastacio da Costa, Lillian Yuri Kumagai
OBJECTIVE: Increasing data suggest that patients with early-stage cervical cancer and favorable pathological characteristics have a low risk of parametrial invasion (PI) and benefit from less radical surgery. Our aim was to evaluate the clinical-pathological factors that are related to PI and identify a group of patients who are at low risk for PI. METHODS: We analyzed a series of 345 patients with stage Ia2 to Ib2 cervical cancer, for which they underwent radical surgery from January 1990 to October 2016 at AC Camargo Cancer Center...
April 6, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28392127/ny-eso-1-expression-predicts-an-aggressive-phenotype-of-ovarian-cancer
#11
J Brian Szender, Antonios Papanicolau-Sengos, Kevin H Eng, Anthony J Miliotto, Amit A Lugade, Sacha Gnjatic, Junko Matsuzaki, Carl D Morrison, Kunle Odunsi
OBJECTIVES: NY-ESO-1 is a cancer testis antigen and a promising target for immunotherapy. The purpose of this study was to determine the expression frequency, immunogenicity, and clinical impact of NY-ESO-1 in ovarian cancer. METHODS: Immunohistochemistry (IHC), reverse-transcription polymerase chain reaction (RT-PCR), and quantitative-PCR (qRT-PCR) were utilized in an ovarian cancer (including Fallopian tube and primary peritoneal cancers) patient cohort; humoral responses against NY-ESO-1 were determined by ELISA...
April 6, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28392126/cancer-testis-antigen-expression-is-shared-between-epithelial-ovarian-cancer-tumors
#12
Arlene E Garcia-Soto, Taylor Schreiber, Natasa Strbo, Parvin Ganjei-Azar, Feng Miao, Tulay Koru-Sengul, Fiona Simpkins, Wilberto Nieves-Neira, Joseph Lucci, Eckhard R Podack
No abstract text is available yet for this article.
April 6, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28392125/vaginal-vs-robotic-hysterectomy-for-patients-with-endometrial-cancer-a-comparison-of-outcomes-and-cost-of-care
#13
C C Nitschmann, F Multinu, J N Bakkum-Gamez, C L Langstraat, J A Occhino, A L Weaver, W A Cliby, A Mariani, S C Dowdy
OBJECTIVE: To compare outcomes and cost for patients with endometrial cancer undergoing vaginal hysterectomy (VH) or robotic hysterectomy (RH), with or without lymphadenectomy (LND). METHODS: Patients undergoing planned VH (and laparoscopic LND) or RH (and robotic LND) between January 2007 and November 2012 were reviewed. Patients with stage IV disease, synchronous cancer, synchronous surgery, or treated with palliative intent were excluded. Patients were objectively triaged to LND per institutional protocol based on frozen section...
April 6, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28392124/surgical-pathological-findings-in-type-1-and-2-endometrial-cancer-an-nrg-oncology-gynecologic-oncology-group-study-on-gog-210-protocol
#14
William T Creasman, Shamshad Ali, David G Mutch, Richard J Zaino, Matthew A Powell, Robert S Mannel, Floor J Backes, Paul A DiSilvestro, Peter A Argenta, Michael L Pearl, Shashikant B Lele, Saketh R Guntupalli, Steven Waggoner, Nick Spirtos, John F Boggess, Robert P Edwards, Virginia L Filiaci, David S Miller
OBJECTIVE: To report clinical and pathologic relationships with disease spread in endometrial cancer patients. METHODS: Surgical candidates with uterine cancer (adenocarcinoma or carcinosarcoma) who were eligible to participate in a surgical pathological study to create a clinically annotated tissue biorepository to support translational and clinical research studies. All patients were to undergo a hysterectomy, bilateral salpingo-oophorectomy, and bilateral pelvic and para-aortic lymphadenectomy...
April 6, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28390821/the-added-value-of-hysterectomy-in-the-management-of-gestational-trophoblastic-neoplasia
#15
Y K Eysbouts, L F A G Massuger, J IntHout, C A R Lok, F C G J Sweep, P B Ottevanger
BACKGROUND: Despite the undoubted effectiveness of chemotherapeutic treatment in gestational trophoblastic neoplasia (GTN), problems related to toxicity of chemotherapy and chemo-resistant disease have led to reconsideration of the use of hysterectomy. Aim of the present study was to evaluate indications for and outcome of hysterectomy in patients with GTN in a nation-wide cohort. METHODS: Between 1977 and 2012, we identified all patients diagnosed with GTN and treated with hysterectomy from the Dutch national databases...
April 5, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28390820/mortality-reduction-and-cost-effectiveness-of-performing-hysterectomy-at-the-time-of-risk-reducing-salpingo-oophorectomy-for-prophylaxis-against-serous-serous-like-uterine-cancers-in-brca1-mutation-carriers
#16
Laura J Havrilesky, Haley A Moss, Junzo Chino, Evan R Myers, Noah D Kauff
OBJECTIVE: To estimate the survival benefit and cost-effectiveness of performing hysterectomy during risk-reducing salpingo-oophorectomy (RRSO) for BRCA1 mutation carriers. METHODS: Based on a recent prospective cohort study indicating an elevated incidence of serous/serous-like uterine cancers among BRCA1 mutation carriers, we constructed a modified Markov decision model from a payer perspective to inform decisions about performance of hysterectomy during RRSO at age 40...
April 5, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28390819/ywhae-rearranged-high-grade-endometrial-stromal-sarcoma-two-center-case-series-and-response-to-chemotherapy
#17
Matthew L Hemming, Andrew J Wagner, Marisa R Nucci, Sarah Chiang, Lu Wang, Martee L Hensley, Suzanne George
OBJECTIVES: YWHAE-rearranged high-grade endometrial stromal sarcoma (HG-ESS) is a rare, recently defined uterine sarcoma harboring t(10;17)(q22;p13) resulting in YWHAE-NUTM2A/B fusion. Chemotherapy sensitivity of metastatic YWHAE-rearranged HG-ESS is unknown. We reviewed the response to chemotherapy in women with YWHAE-rearranged HG-ESS to provide guidance for clinical management. METHODS: We retrospectively identified patients diagnosed with YWHAE-rearranged HG-ESS who received treatment for metastatic disease at our institutions...
April 5, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28385388/microrna-138-is-a-potential-biomarker-and-tumor-suppressor-in-human-cervical-carcinoma-by-reversely-correlated-with-tcf3-gene
#18
Huiqin Li, Yang Sheng, Ying Zhang, Nan Gao, Xiangyun Deng, Xiugui Sheng
BACKGROUND: The aim of our work is to identify the functional mechanism of microRNA-138 (miR-138) in human cervical cancer. METHODS: MiR-138 expression was investigated by qRT-PCR in cervical cancer cell lines and human tumors. Correlations of patients' clinicopathological factors and overall survival with miR-138 expression were analyzed. In SiHa and HeLa cells, miR-138 was either upregulated or downregulated to evaluate its regulations on cervical cancer in vitro proliferation, invasion and in vivo xenograft growth...
April 3, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28381342/minimally-invasive-compared-with-open-surgery-in-patients-with-borderline-ovarian-tumors
#19
Taejong Song, Min Kyu Kim, Yong Wook Jung, Bo Seong Yun, Seok Ju Seong, Chel Hun Choi, Tae-Joong Kim, Jeong-Won Lee, Duk-Soo Bae, Byoung-Gie Kim
OBJECTIVE: To compare the surgical and oncological outcomes between laparoscopic (single-port or multi-port) and open surgery in the treatment of patients with borderline ovarian tumors (BOTs). METHODS: A retrospective analysis was performed on 687 patients who underwent single-port laparoscopy (n=89), multi-port laparoscopy (n=223), or open surgery (n=375) due to BOTs. RESULTS: The age, tumor size, tumor marker, and the proportions of radical surgery rate and surgical staging were significantly lower in the single-port laparoscopy and multi-port laparoscopy groups compared with those in the open surgery group (all P<0...
April 2, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28377094/t-cell-target-antigens-across-major-gynecologic-cancers
#20
REVIEW
Alba Rodriguez-Garcia, Nicholas G Minutolo, John M Robinson, Daniel J Powell
Immunotherapies have achieved remarkable success in treating different forms of cancer including melanoma, non-small cell lung carcinoma, bladder cancer, synovial cell sarcoma, and multiple myeloma using immune checkpoint blockade or gene-engineered T-cells. Although gynecologic cancers have not been historically classified as immunogenic tumors, growing evidence has shown that they are in fact able to elicit endogenous antitumor immune responses suggesting that patients with these cancers may benefit from immunotherapy...
April 2, 2017: Gynecologic Oncology
journal
journal
23122
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"